12/5
04:12 pm
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/5
04:01 pm
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/4
01:58 pm
ntla
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]
Low
Report
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]
12/2
01:30 pm
ntla
Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]
Low
Report
Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]
11/30
03:33 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at
Wall S
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at
Wall S
11/29
09:28 am
ntla
Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade [Yahoo! Finance]
Medium
Report
Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade [Yahoo! Finance]
11/25
08:55 am
ntla
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress [Yahoo! Finance]
Low
Report
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress [Yahoo! Finance]
11/19
06:10 pm
ntla
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight [Yahoo! Finance]
Medium
Report
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight [Yahoo! Finance]
11/15
10:04 am
ntla
2 Beaten-Down Stocks to Avoid Right Now [Yahoo! Finance]
Low
Report
2 Beaten-Down Stocks to Avoid Right Now [Yahoo! Finance]
11/13
12:11 pm
ntla
Should You Buy the Dip in Intellia Therapeutics Stock? [Yahoo! Finance]
Medium
Report
Should You Buy the Dip in Intellia Therapeutics Stock? [Yahoo! Finance]
11/12
08:07 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.
11/12
06:43 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at Evercore ISI to a "hold" rating.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at Evercore ISI to a "hold" rating.
11/11
03:35 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "hold" rating reaffirmed by analysts at Jones Trading.
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "hold" rating reaffirmed by analysts at Jones Trading.
11/11
02:40 pm
ntla
Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program [Yahoo! Finance]
Medium
Report
Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program [Yahoo! Finance]
11/11
07:01 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was given a new $8.00 price target on by analysts at Evercore ISI.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was given a new $8.00 price target on by analysts at Evercore ISI.
11/10
03:40 pm
ntla
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy [Yahoo! Finance]
Low
Report
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy [Yahoo! Finance]
11/10
03:17 pm
ntla
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Low
Report
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
11/10
12:06 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $14.00 price target on the stock, down previously from $25.00.
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $14.00 price target on the stock, down previously from $25.00.
11/10
08:03 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at HC Wainwright from $18.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at HC Wainwright from $18.00 to $15.00. They now have a "buy" rating on the stock.
11/8
05:25 pm
ntla
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema [Yahoo! Finance]
Low
Report
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema [Yahoo! Finance]
11/8
05:13 pm
ntla
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Low
Report
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
11/8
01:17 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at
Wall S
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at
Wall S
11/7
06:22 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Chardan Capital from $48.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Chardan Capital from $48.00 to $26.00. They now have a "buy" rating on the stock.
11/7
02:22 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Wells Fargo & Company from $17.00 to $12.00. They now have an "equal weight" rating on the stock.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Wells Fargo & Company from $17.00 to $12.00. They now have an "equal weight" rating on the stock.
11/7
02:22 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $9.00. They now have a "sector perform" rating on the stock.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $9.00. They now have a "sector perform" rating on the stock.